Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs

Area of Science:

• Pharmacology
• Urology
• Health Economics

Background:

• Enlarged prostate (EP) management often involves combination therapy with alpha blockers and 5-alpha reductase inhibitors (5ARIs).
• Assessing medication discontinuation is crucial for understanding treatment effectiveness and healthcare costs.

Purpose of the Study:

• To compare the likelihood and timing of alpha blocker discontinuation in patients with EP receiving combination therapy with dutasteride or finasteride plus an alpha blocker.

Main Methods:

• Retrospective analysis of a large, nationally representative healthcare database (PharMetrics).
• Inclusion criteria: male patients >50 years with EP, on alpha blocker therapy, initiated on dutasteride or finasteride between 1999-2005.
• Study duration: up to 12 months to evaluate alpha blocker discontinuation.

Main Results:

• At 1 year, 48.9% of dutasteride patients and 58.7% of finasteride patients remained on alpha blocker therapy.
• Dutasteride patients were 19.9% more likely to discontinue alpha blocker therapy compared to finasteride patients within 365 days.
• Overall, 56.7% of patients remained on alpha blockers for 6 months.

Conclusions:

• Combination therapy with dutasteride and an alpha blocker leads to earlier discontinuation of the alpha blocker compared to finasteride.
• Earlier alpha blocker discontinuation may reduce pharmacotherapy costs while maintaining symptom control for EP.
• This finding has implications for cost savings in healthcare plans managing enlarged prostate.